The indolent lymphoma market is witnessing steady growth driven by the increasing prevalence of slow-growing non-Hodgkin lymphomas and rising awareness about early diagnosis. Additionally, the launch of therapies such as AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat (Xynomic Pharmaceuticals), ZE50-0134 (Eilean Therapeutics), NVG-111 (NovalGen), and others will further fuel the market.

LAS VEGAS, Oct. 16, 2025 /PRNewswire/ — DelveInsight’s Indolent Lymphoma Market Insights report includes a comprehensive understanding of current treatment practices, indolent lymphoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).

Indolent Lymphoma Market Summary

• The market size for indolent lymphoma in the leading markets is expected to grow significantly by 2034.
• The United States accounted for the highest indolent lymphoma treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.
• Indolent lymphoma accounts for 41% of all NHL cases in North America and Northern Europe.
• Leading indolent lymphoma companies developing emerging therapies, such as AstraZeneca, BeiGene, Xynomic Pharmaceuticals, Enterome, NovalGen, Eilean Therapeutics, and others, are developing new therapy for indolent lymphoma that can be available in the indolent lymphoma market in the coming years.
• The promising indolent lymphoma therapies in clinical trials include AZD0486, BGB-16673, Sonrotoclax + Zanubrutinib, Abexinostat, EO2463, NVG-111, ZE50-0134, and others.

Discover the indolent lymphoma new treatment @ New Treatments for Indolent Lymphoma

Key Factors Driving the Growth of the Indolent Lymphoma Market

Advancements in Targeted and Immunotherapy Treatments

The development of novel therapies, including oral and injectable medications, has improved the management of indolent lymphoma. These treatments offer greater efficacy, reduced side effects, and more precise mechanisms, leading to enhanced patient outcomes and satisfaction.

Technological Innovations in Molecular Profiling

Advancements in molecular profiling techniques, such as next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis, have enabled the identification of genetic alterations contributing to disease development and progression. These technologies guide targeted treatment approaches, improving therapeutic outcomes.

Rising Indolent Lymphoma Clinical Trial Activity

Several potential therapies are being investigated for the management of indolent lymphoma. The anticipated launch of the promising candidate like AZD0486, EO2463, Abexinostat, CTX112, Docirbrutinib, NVG-111, and others during the forecast period (2025–2034) is expected to bring about a significant shift in the market dynamics of indolent lymphoma.

Indolent Lymphoma Market Analysis

The management of indolent lymphoma, a slow-growing form of non-Hodgkin lymphoma, has advanced considerably, providing a variety of treatment options tailored to disease stage, symptom burden, and patient health. For early-stage or asymptomatic patients, a “watch and wait” strategy is often recommended, as immediate therapy may not improve outcomes. When treatment becomes necessary, monoclonal antibodies are the standard first-line option, either alone or combined with chemotherapy regimens such as bendamustine, CHOP, or CVP.

For relapsed or refractory cases, targeted therapies play a central role, including BTK inhibitors (e.g., ibrutinib, zanubrutinib), PI3K inhibitors (e.g., copanlisib, duvelisib, umbralisib), and EZH2 inhibitors like tazemetostat, particularly in EZH2-mutated follicular lymphoma. In more advanced disease, CAR T-cell therapies (e.g., axi-cel, liso-cel) and bispecific antibodies such as epcoritamab and mosunetuzumab have demonstrated high response rates in both clinical trials and real-world settings. Other approaches, including radioimmunotherapy and autologous stem cell transplantation, may be appropriate for selected patients. Active research into immunotherapies and precision medicine continues to broaden treatment possibilities, aiming to achieve deeper, longer-lasting remissions with reduced toxicity.

To know more about indolent lymphoma treatment options, visit @ Approved Indolent Lymphoma Drugs

Indolent Lymphoma Competitive Landscape

Several potential therapies are being investigated for the management of indolent lymphoma. The anticipated launch of the promising candidate like AZD0486 (AstraZeneca), EO2463 (Enterome), Abexinostat (Xynomic Pharmaceuticals), ZE50-0134 (Eilean Therapeutics), NVG-111 (NovalGen), and others during the forecast period (2025–2034) is expected to bring about a significant shift in the market dynamics of indolent lymphoma.

AstraZeneca’s AZD0486 (previously TNB-486) is a next-generation, fully human IgG4 CD19xCD3 bispecific T-cell engager (TCE) that features a unique low-affinity anti-CD3 component. This design aims to minimize cytokine release while maintaining strong T-cell–mediated killing of malignant B cells. Its silenced Fc region prevents nonspecific interactions and antibody-dependent cellular cytotoxicity, and provides a prolonged half-life that supports intermittent dosing.

Enterome’s EO2463 is a novel, off-the-shelf OncoMimics active immunotherapy composed of four synthetic peptides. These microbial-derived, non-self peptides mimic CD8 HLA-A2 epitopes that resemble B cell–specific markers CD20, CD22, CD37, and CD268 (BAFF receptor). The therapy also incorporates a CD4+ helper peptide, universal cancer peptide 2 (UCP2), to enhance immune activation.

The anticipated launch of these emerging therapies are poised to transform the indolent lymphoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the indolent lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about therapy for indolent lymphoma @ Indolent Lymphoma Clinical Trials

Recent Developments in the Indolent Lymphoma Market

• In August 2025, Bristol Myers Squibb announced FDA has accepted the supplemental biologics license application (sBLA) for BREYANZI (lisocabtagene maraleucel) as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
• In June 2025, Enterome presented positive interim results for its OncoMimic immunotherapy EO2463 from Cohorts 1 and 4 of the ongoing open label Phase I/II SIDNEY trial in patients with indolent non-Hodgkin lymphoma (iNHL), at the International Conference on Malignant Lymphoma (ICML) in Lugano.
• In February 2025, Regeneron Pharmaceuticals announced that it has resubmitted the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company anticipates a decision from the FDA by the second half of 2025.
• In February 2025, Eli Lilly announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for JAYPIRCA (pirtobrutinib), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a BTK inhibitor.

What is Indolent Lymphoma?

Indolent lymphoma is a slow-developing form of non-Hodgkin lymphoma that mainly involves B cells and can take several years to advance. Key subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL). Many individuals may experience no symptoms for extended periods, but common signs can include painless swollen lymph nodes, fatigue, night sweats, unintentional weight loss, and frequent infections. The precise cause is not fully understood, though potential risk factors include genetic mutations, immune system irregularities, chronic infections, or exposure to certain chemicals or radiation. Because it progresses slowly, indolent lymphoma is often carefully monitored, with treatment initiated only if symptoms escalate or the disease shows increased activity.

Indolent Lymphoma Epidemiology Segmentation

The indolent lymphoma epidemiology section provides insights into the historical and current indolent lymphoma patient pool and forecasted trends for the leading markets. The indolent lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

• Total Incidence Cases of Indolent Lymphoma
• Type-specific Cases of Indolent Lymphoma
• Stage-specific Cases of Indolent Lymphoma
• Total Treated Cases of Indolent Lymphoma

Scope of the Indolent Lymphoma  Market Report

• Therapeutic Assessment: Indolent Lymphoma current marketed and emerging therapies
• Indolent Lymphoma Market Dynamics: Key Market Forecast Assumptions of Emerging Indolent Lymphoma Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Indolent Lymphoma Market Access and Reimbursement

Download the report to understand which factors are driving indolent lymphoma therapeutics market trends @ Indolent Lymphoma Market Trends

Table of Contents

Related Reports

Indolent Lymphoma Clinical Trial Analysis

Indolent Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key indolent lymphoma companies, including AstraZeneca, BeiGene, Xynomic Pharmaceuticals, Enterome, NovalGen, Eilean Therapeutics, Eli Lilly, Janssen Biotech, Pharmacyclics (an AbbVie company), Genmab, among others.

Non-Hodgkin’s Lymphoma Market

Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-Hodgkin’s lymphoma companies, including Soligenix, Innate Pharma, Nurix Therapeutics, AstraZeneca, Merck, Prescient Therapeutics, Kite Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member of Roche), Bristol Myers Squibb, among others.

Follicular Lymphoma Market

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key follicular lymphoma Market companies, including Merck Sharp and Dohme, AstraZeneca, CRISPR Therapeutics, BeiGene, Nektar Therapeutics, NovalGen, Carna Biosciences, Allogene Therapeutics, Xynomic Pharmaceuticals, Bristol-Myers Squibb, Incyte Corporation, among others.

Marginal Zone Lymphoma Market

Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MZL Market companies, including Celgene Corporation, AbbVie, Janssen Biotech, TG Therapeutics, Bayer, Roche Pharma, Gilead Sciences, Merck Sharp & Dohme, Cellectar Biosciences, Innovent Biologics, Bristol-Myers Squibb, Astrazeneca, Nordic Nanovector, AbbVie, InnoCare Pharma, Merck KGaA, ArQule, Merck, Verastem, Secura Bio, BeiGene, MEI Pharma, NantKwest, ImmunityBio, Loxo Oncology, Eli Lilly, TriSalus Life Sciences, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP